# A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

> **NCT07123129** · PHASE1 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Malignancy

## Interventions

- **DRUG:** SHR-7782 Injection

## Key facts

- **NCT ID:** NCT07123129
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-28
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123129, "A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07123129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*